Kaposi Sarcoma: Doxil
This drug is effective for KS. It was first reported in the early 1990 and FDA approved in 1995. DOXIL is indicated for the treatment of AIDS-related Kaposi’s sarcoma in patients after failure of prior systemic chemotherapy or intolerance to such therapy.The liposomal technology has resulted in higher response rates with less cardiac and myelotoxicity for both liposomal doxorubicin and liposomal daunorubicin because of their more targeted nature and esponse rates of up to 80% can be seen with either of these drugs. OXIL is indicated for the treatment of AIDS-related Kaposi’s sarcoma in patients after failure of prior systemic chemotherapy or intolerance to such therapy. It is an off-label med necessary drug for disseminated KS.
James ND et al, Liposomal doxorubicin (Doxil): an effective new treatment for Kaposi’s sarcoma in AIDS.Clin Oncol (R Coll Radiol). 1994;6(5):294-6.
Martin-Carbonero L, Barrios A, Saballs P, Sirera G, Santos J, Palacios R, et al. Pegylated liposomal doxorubicin plus high active antiretroviral therapy verusus Highy active antiretroviral therapy alone in HIV patients with Kaposi’s sarcoma. AIDS. 2004. 18:410-417.
Uldrick TS, Whitby D. Update on KSHV epidemiology, Kaposi Sarcoma pathogenesis, and treatment of Kaposi Sarcoma. Cancer Lett. 2011 Jun 28. 305(2):150-62.
Guidelines on the Treatment of Skin and Oral HIV-Associated Conditions in Children and Adults
Geneva: World Health Organization; 2014.
ISBN-13: 978-92-4-154891-5